Detalhe da pesquisa
1.
Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the vastus lateralis (lateral thigh) muscles of healthy adult participants.
Antimicrob Agents Chemother
; 68(1): e0078123, 2024 Jan 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38038460
2.
Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP.
Antimicrob Agents Chemother
; : e0147523, 2024 May 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38709006
3.
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study.
Clin Infect Dis
; 76(9): 1646-1654, 2023 05 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36660819
4.
Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure.
Clin Infect Dis
; 77(10): 1423-1431, 2023 11 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37340869
5.
Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.
Lancet
; 399(10337): 1779-1789, 2022 05 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35378077
6.
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
N Engl J Med
; 382(12): 1124-1135, 2020 03 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-32130806
7.
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.
N Engl J Med
; 382(12): 1112-1123, 2020 03 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-32130809
8.
Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting cabotegravir and rilpivirine in clinical trials.
HIV Med
; 24(5): 568-579, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36411596
9.
Safety, Tolerability, Pharmacokinetics, and Acceptability of Oral and Long-Acting Cabotegravir in HIV-Negative Chinese Men.
Antimicrob Agents Chemother
; 66(3): e0205721, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35129374
10.
Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the In Vitro Potency of Cabotegravir or Rilpivirine.
Antimicrob Agents Chemother
; 66(3): e0170221, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34978890
11.
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Lancet
; 396(10267): 1994-2005, 2021 12 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33308425
12.
Multiparametric magnetic resonance imaging to characterize cabotegravir long-acting formulation depot kinetics in healthy adult volunteers.
Br J Clin Pharmacol
; 88(4): 1655-1666, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34240449
13.
Multicompartmental pharmacokinetic evaluation of long-acting cabotegravir in healthy adults for HIV preexposure prophylaxis.
Br J Clin Pharmacol
; 88(4): 1667-1678, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34240467
14.
Population pharmacokinetics of cabotegravir following administration of oral tablet and long-acting intramuscular injection in adult HIV-1-infected and uninfected subjects.
Br J Clin Pharmacol
; 88(10): 4607-4622, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35695476
15.
Long-Acting Cabotegravir Protects Macaques Against Repeated Penile Simian-Human Immunodeficiency Virus Exposures.
J Infect Dis
; 222(3): 391-395, 2020 07 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32128569
16.
Evaluation of the effect of UGT1A1 polymorphisms on the pharmacokinetics of oral and long-acting injectable cabotegravir.
J Antimicrob Chemother
; 75(8): 2240-2248, 2020 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32361755
17.
Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks.
AIDS Behav
; 24(12): 3533-3544, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32447500
18.
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.
PLoS Med
; 15(11): e1002690, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30408115
19.
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
Lancet
; 390(10101): 1499-1510, 2017 Sep 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-28750935
20.
Lack of effect of oral cabotegravir on the pharmacokinetics of a levonorgestrel/ethinyl oestradiol-containing oral contraceptive in healthy adult women.
Br J Clin Pharmacol
; 83(7): 1499-1505, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28087972